Table 3.
A: Main baseline demographics of matched cohorts comparing BP-CCBs with verapamil or diltiazem. A: patients with no prior neuropsychiatric diagnosis. B: patients with a prior neuropsychiatric diagnosisa.
| A: no prior neuropsychiatric diagnosis | B: with prior neuropsychiatric diagnosis | |||
|---|---|---|---|---|
| BP-CCB | Verapamil or diltiazemb | BP-CCB | Verapamil or diltiazemc | |
| Cohort size (n) | 49,987 | 49,987 | 26,094 | 26,094 |
| Age at index (y, SD) | 59.8 (17.0) | 60.4 (15.4) | 57.5 (16.4) | 57.7 (14.7) |
| Sex (M:F %) | 43:57 | 44:56 | 40:60 | 40:60 |
| Race (W,B,O %)d | 56, 27, 17 | 54, 29, 17 | 59, 29, 12 | 58, 30, 12 |
| Blood pressure | 137/77e | 134/76e | 138/78f | 133/77f |
| Body mass index (SD) | 30.3 (7.0) | 30.6 (7.3) | 31.2 (7.6) | 31.6 (8.0) |
| Prior psychotic disorder (%) | 0 | 0 | 3 | 3 |
| Prior affective disorder (%) | 0 | 0 | 31 | 31 |
| Prior anxiety disorder (%) | 0 | 0 | 31 | 31 |
| Prior substance use disorder (%) | 0 | 0 | 27 | 26 |
| Prior sleep disorder (%) | 0 | 0 | 33 | 33 |
| Prior delirium (%) | 0 | 0 | 4 | 4 |
| Prior dementia (%) | 0 | 0 | 3 | 4 |
| Prior movement disorder (%) | 0 | 0 | 6 | 6 |
aSee footnote a to Table 1.
b35% on verapamil, 67% on diltiazem. Numbers exceed 100% as some patients prescribed both drugs.
c38% on verapamil, 66% on diltiazem. Numbers exceed 100% as some patients prescribed both drugs.
dW: white. B: black. O: other or not known.
eStandard difference = 0.13.
fStandard difference = 0.20.